It will grow to $9.02 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save ...

Spinal Muscular Atrophy treatment is evolving fast, with gene therapy, oral drugs, and next-gen muscle enhancers offering new hope and long-term outcomes. With each breakthrough in SMA treatment, we ...

The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...

In perhaps a first in the country, a newborn found carrying the SMN1 gene mutation for Spinal Muscular Atrophy (SMA) through prenatal genetic screening is being administered presymptomatic ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

In SMA, progressive muscle weakness and atrophy lead to symptoms such as difficulty with movement, speech, and swallowing. The condition is caused by mutations in the SMN1 gene, which result in a ...

Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.